| 系统性硬皮病相关间质性肺病的药物治疗进展 |
| |
| 引用本文： | 鲁静浩(综述),周行,刘超凡,朱鹭冰(审校),李明. 系统性硬皮病相关间质性肺病的药物治疗进展[J]. 复旦学报(医学版), 2018, 45(5): 740-743. DOI: 10.3969/j.issn.1672-8467.2018.05.023 |
| |
| 作者姓名： | 鲁静浩(综述) 周行 刘超凡 朱鹭冰(审校) 李明 |
| |
| 作者单位： | 复旦大学附属中山医院皮肤科 上海 200032 |
| |
| 基金项目： | 国家自然科学基金(30901291) |
| |
| 摘 要： | 系统性硬皮病(systemic sclerosis,SSc)是一种表现为皮肤硬化和内脏器官纤维化的自身免疫疾病,SSc相关间质性肺病(SSc-related interstitial lung disease,SSc-ILD)是患者的主要死因之一,其发生机制不明,治疗难度大。本文介绍了近年来SSc-ILD常用药(糖皮质激素、环磷酰胺及硫唑嘌呤)在临床研究中的新进展,以及有关新型药(霉酚酸酯、吡非尼酮、B细胞靶向治疗药物、抗IL-6受体抗体药物、甲磺酸伊马替尼和巴利昔单抗)治疗SSc-ILD的探索性研究进展。
|
| 关 键 词： | 系统性硬皮病 间质性肺病 药物治疗 |
The progress of drug therapy in systemic sclerosis-related interstitial lung disease |
| |
| LU Jing-hao,ZHOU Xing,LIU Chao-fan,ZHU Lu-bing,LI Ming. The progress of drug therapy in systemic sclerosis-related interstitial lung disease[J]. Fudan University Journal of Medical Sciences, 2018, 45(5): 740-743. DOI: 10.3969/j.issn.1672-8467.2018.05.023 |
| |
| Authors: | LU Jing-hao ZHOU Xing LIU Chao-fan ZHU Lu-bing LI Ming |
| |
| Affiliation: | Department of Dermatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China |
| |
| Abstract: | Systemic sclerosis (SSc) is an autoimmune disease characterized by skin sclerosis and visceral fibrosis.SSc-related interstitial lung disease (SSc-ILD) is one of the main cause of mortality in patients with SSc.The pathogenesis of SSc-ILD is unclear,and its treatment is still a challenge for clinicians.This review describes the clinical progress in commonly-used drugs of SSc-ILD like glucocorticoid,cyclophosphamide and azathioprine,and exploratory study of the new drugs like mycophenolate mofetil,pirfenidone,B cell depletion,the anti-interleukin-6 receptor antibody,imatinib mesylate and basiliximab. |
| |
| Keywords: | systemic sclerosis interstitial lung disease drug therapy |
|
| 点击此处可从《复旦学报(医学版)》浏览原始摘要信息 |
|
点击此处可从《复旦学报(医学版)》下载免费的PDF全文 |
|
